AU1758683A - 1,4-benzthiazine derivatives - Google Patents

1,4-benzthiazine derivatives

Info

Publication number
AU1758683A
AU1758683A AU17586/83A AU1758683A AU1758683A AU 1758683 A AU1758683 A AU 1758683A AU 17586/83 A AU17586/83 A AU 17586/83A AU 1758683 A AU1758683 A AU 1758683A AU 1758683 A AU1758683 A AU 1758683A
Authority
AU
Australia
Prior art keywords
halogen
aryl
hydroxyl
alkyl
mono
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU17586/83A
Inventor
Wolf-Dieter Busse
Rudi Grutzmann
Mithat Mardin
Horst Meyer
Ekkehard Niemers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of AU1758683A publication Critical patent/AU1758683A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dental Preparations (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
  • Eyeglasses (AREA)
  • Ink Jet (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

1. 4H-1,4-Benzothiazines of the formula see diagramm : EP0100527,P16,F4 in which R**1 denotes hydrogen, aryl with 6 to 20 carbon atoms, which can optionally be mono- to trisubstituted by halogen, trifluoromethyl or nitro, 2-thienyl, 3-thienyl, 2-furyl, 3-furyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl or 5-pyrimidyl, which can optionally be mono- or polysubstituted by alkyl, alkoxy, hydroxyl or halogen, cyano or the group see diagramm : EP0100527,P16,F6 in which R**6 represents alkyl (C1 to C8 ), aryl (C6 to C20 ), amino, pyrrolidino, piperidino, morpholino, cycloalkoxy or the radical -O-CH2 -R**8 in which R**8 denotes straight-chain or branched alkyl with 1 to 7 carbon atoms, which is optionally mono- to trisubstituted by halogen, C6 to C20 -aryl, hydroxyl, alkoxy, alkylthio or cyano, R**2 denotes alkyl (C1 to C8 ), which is optionally mono- to trisubstituted by halogen, pyrrolidino, piperidiono, aryl (C1 to C20 ) or by the group in which R**7 represents aryl (C6 to C20 ), hydroxyl, amino, dialkylamino, pyrrolidino, piperidino or morpholino, R**3 denotes hydrogen or one of the groups mentioned under R**2 , and R**4 and R**5 are identical or different and denote hydrogen, halogen, hydroxyl, alkoxy, nitro or cyano, or one of the groups mentioned under R**2 , for therapeutic use.
AU17586/83A 1982-08-04 1983-08-04 1,4-benzthiazine derivatives Abandoned AU1758683A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE32291213 1982-08-04
DE19823229121 DE3229121A1 (en) 1982-08-04 1982-08-04 4H-1,4-BENZOTHIAZINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT

Publications (1)

Publication Number Publication Date
AU1758683A true AU1758683A (en) 1984-02-09

Family

ID=6170116

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17586/83A Abandoned AU1758683A (en) 1982-08-04 1983-08-04 1,4-benzthiazine derivatives

Country Status (14)

Country Link
EP (1) EP0100527B1 (en)
JP (1) JPS5944368A (en)
KR (1) KR840005727A (en)
AT (1) ATE24724T1 (en)
AU (1) AU1758683A (en)
DE (2) DE3229121A1 (en)
DK (1) DK354483A (en)
ES (1) ES524708A0 (en)
FI (1) FI832782A (en)
GR (1) GR79356B (en)
IL (1) IL69389A0 (en)
NO (1) NO832664L (en)
PT (1) PT77096B (en)
ZA (1) ZA835674B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3426564A1 (en) * 1984-07-19 1986-01-30 Bayer Ag, 5090 Leverkusen USE OF 4H-1,4-Benzothiazines FOR PREVENTION AND TREATMENT OF RESPIRATORY DISORDERS, inflammation / RHEUMA, THROMBOEMBOLIC ILLNESSES AND ischemia infarcts, HERZRHYTHMUSSTOERUNGEN, ATHEROSCLEROSIS AND dermatoses, PURPOSE AND ACTIVE DRUGS TO THIS IN THESE PRODUCTS CONTAIN
DE3540702A1 (en) * 1985-11-16 1987-05-21 Bayer Ag 1H-PYRIDO- (2,3-B) (1,4) THIAZINE
DE3545097A1 (en) * 1985-12-19 1987-07-02 Bayer Ag 1-H-PYRIDO- (3,2-B) (1,4) THIAZINE

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4397849A (en) * 1980-12-30 1983-08-09 Fujisawa Pharmaceutical Co., Ltd. Benzothiazine derivatives
DE3111487A1 (en) * 1981-03-24 1982-12-30 Bayer Ag, 5090 Leverkusen METHOD FOR PRODUCING 2,3-DIHYDRO-4H-1,4 DIHYDRO-1,4-BENZOTHIAZINES

Also Published As

Publication number Publication date
EP0100527A1 (en) 1984-02-15
DE3368925D1 (en) 1987-02-12
PT77096A (en) 1983-08-01
DK354483A (en) 1984-02-05
KR840005727A (en) 1984-11-16
ATE24724T1 (en) 1987-01-15
DK354483D0 (en) 1983-08-03
ZA835674B (en) 1984-04-25
ES8404682A1 (en) 1984-05-01
PT77096B (en) 1986-03-12
FI832782A (en) 1984-02-05
NO832664L (en) 1984-02-06
EP0100527B1 (en) 1987-01-07
DE3229121A1 (en) 1984-02-09
JPS5944368A (en) 1984-03-12
IL69389A0 (en) 1983-11-30
FI832782A0 (en) 1983-08-02
GR79356B (en) 1984-10-22
ES524708A0 (en) 1984-05-01

Similar Documents

Publication Publication Date Title
BR9814361A (en) Inhibition of raf kinase using heterocyclic urea substituted by heteroaryl aryl
DK161197C (en) 1ALFA-HYDROXY-2-SUBSTITUTED VITAMIN D3 DERIVATIVES AND PROCEDURES FOR THE PREPARATION OF THESE
ZA881077B (en) Macromolecular platinum antitumor compounds
IT8022331A0 (en) DRYING OR RESPECTIVELY BY PROCEDURE FOR THE TREATMENT OF LIME. THERMAL, ESPECIALLY FOR THE
ES2121993T3 (en) DERIVATIVES OF 4-OXO-2-THIOXOIMIDAZOLIDINE AS INHIBITING SUBSTANCES OF THE BLOOD PLATE AGGREGATION.
ES8601205A1 (en) 2-Piperazino-pteridines, processes for their preparation and medicaments containing these compounds.
EP0200024A3 (en) 3-cyano-pyridines, process for their preparation and their pharmaceutical use
ZA864041B (en) Pyridine derivatives,their preparation and their use
PT75074A (en) Process for preparing cestain pyrimidone derivatives and composition containing their
AU1758683A (en) 1,4-benzthiazine derivatives
NO156615C (en) PROCEDURE FOR REGULATING POCKET GRINDERS.
SG29987G (en) N-((4-(3-substituted pyridyl) piperazino) alkyl) azaspirodecanediones
DE3471657D1 (en) Substituted phenyl-2-(1h)-pyrimidinones, process for their preparation and their use, and preparations containing these compounds
ZA873198B (en) Pyridine compounds
DE3876381D1 (en) USE OF 2-PYRIMIDINYL-1-PIPERAZINE DERIVATIVES.
SE7407296L (en)
YU82676A (en) Furnace for thermally treating solid lump fuel
FR2518543B1 (en) PROCESS FOR THE PREPARATION OF 3- (3,6-DIHYDRO-1 (2H) -PYRIDYL) -PYRIMIDINES 3-OXIDES
JPS5324098A (en) Separation of proteins
ES8106156A1 (en) Oxadiazolotriazine derivatives.
ES8707187A1 (en) Process for 4-amino quinolines.
FR2492826B1 (en) MONO- AND BIS- (DIALCOXY-1,3-PROPYL-2) PHOSPHORIC ACIDS AND MINERAL SALTS AND THE PROCESS FOR OBTAINING THEM
GB2070600B (en) Lminium salts and process for preparing 5-(cyano or carbomyl)-(3,4-bipyridin)-6(1h)-one
BE893833A (en) PROCESS FOR THE PREPARATION OF 3- (3,6-DIHYDRO-1 (2H) - PYRIDYL) -PYRIMIDINES 3-OXIDES
YU44287B (en) Process for preparing 2,4,6-trisubstituted derivatives 5-(3,4,5-trimetoxibenzyl)-pyrimidine